Category: Cancer Awareness

GD2: A Critical Biomarker and Therapeutic Target – What the Latest Evidence Shows

New scientific data highlight GD2 — a glycolipid biomarker expressed in specific cancer cells — as one of the most promising therapeutic targets in modern oncology. A recent review published in an international scientific journal brings together the latest findings on the use of GD2 in immunotherapies, CAR-T cell treatments, monoclonal antibodies, and other innovative approaches.

What is GD2 and why does it matter?

GD2 is a molecule known as disialoganglioside-2, found in high concentrations on the surface of certain cancer cells. This makes it particularly valuable as a target for personalized immunotherapies, as treatments can “recognize” and destroy GD2-positive cells while sparing healthy tissues.

Cancers with high GD2 expression include:
• Neuroblastoma
• Osteosarcoma
• Melanoma
• Breast cancer (triple-negative in some cases)
• Certain lung cancers
• Rare pediatric tumors

In neuroblastoma — one of the most common pediatric cancers — GD2-directed antibody therapy has already improved survival in high-risk patients.

The new scientific review maps the current progress in GD2-targeted therapies, highlighting the technologies showing the strongest clinical potential. GD2-directed monoclonal antibodies, already effective in children with neuroblastoma, are evolving into more precise and safer versions, aiming to expand their use in adult tumors as well. The review also presents updated data from clinical trials of GD2-directed CAR-T cells: despite challenges such as toxicity, tumor escape, and limited persistence, newer CAR-T generations demonstrate improved safety, deeper penetration into solid tumors, and especially promising outcomes in pediatric patients.

The review further examines combination immunotherapies that pair GD2 targeting with radiotherapy, chemotherapy, or immune checkpoint inhibitors, offering enhanced effectiveness against resistant tumors. Finally, emerging platforms are described — including bispecific antibodies, “smart” nanoparticle-based strategies, and drug-delivery technologies that target only GD2-positive cells — expanding the therapeutic landscape and opening new avenues for future applications.

What does this mean for patients?

GD2-targeted therapy is no longer theoretical — it is already a reality in certain pediatric cancers and is rapidly expanding into other tumor types.

Key benefits for patients include:
• greater precision with reduced toxicity
• the potential for highly individualized treatment based on tumor profile
• new hope for tumors that remain difficult to treat with existing methods
• improved survival prospects, especially for children

For pediatric and young adult patients — a group with historically limited and often highly burdensome treatment options — GD2-directed therapies represent a significant step forward.

Despite the important progress made, several challenges remain. These include side effects such as neuropathic pain, tumor resistance or escape from targeting, the high cost and limited availability of advanced treatments, and the need for large, multi-center clinical trials to produce more robust and generalizable data. Still, research activity is intensifying, with dozens of clinical studies currently ongoing worldwide.

Within this evolving landscape, Kapa3 remains committed to providing accurate, accessible, and compassionate information to patients and families, particularly those facing severe, rare, or pediatric cancers. Advances in GD2-targeted therapies are opening new pathways for children and young people with limited options today , showcasing the power and potential of immunotherapy. At the same time, they highlight the urgent need for equitable access to innovative treatments for patients in Greece.

Kapa3 will continue to follow scientific developments closely and keep the community informed in a clear, reliable, and human-centered way.

Sources: Here

Text/Adaptation: Ifiyenia Anastasiou for Kapa3

Artificial Intelligence (AI) is transforming the fight against cancer.The European Cancer Organisation’s “Harnessing AI for Cancer Care in Europe” report

Artificial Intelligence (AI) is transforming the fight against cancer, enabling machines to learn, reason, and assist humans in detecting, diagnosing and treating the disease more accurately and efficiently. It works by analysing vast amounts of data, learning patterns, and making predictions or recommendations to support human decision-making.

Cancer care is rapidly transforming with the use of AI, which serves as a powerful tool in prevention, detection, treatment and research of the disease. The European Cancer Organisation’s “Harnessing AI for Cancer Care in Europe” report states that AI has the potential to transform every stage of the cancer pathway. Simultaneously, the report emphasises the need for AI to be used responsibly, by protecting patients, upholding ethical standards, and aligning with European values, to ensure its benefits are delivered fairly and effectively across healthcare systems.

The Promise of AI in Cancer Care

The report highlights several ways AI can improve cancer outcomes across the care pathway. In primary prevention, AI can analyse genetic, environmental, and lifestyle data to identify high-risk patients and guide preventive strategies before symptoms appear. For early detection, AI can dramatically speed up screening, reducing test interpretation from days to hours, improving accuracy, and lowering missed diagnoses. In diagnostics, deep-learning models trained on large datasets can detect even the smallest lesions, prioritise urgent cases, and support more precise diagnoses. AI also enables personalised treatment by integrating tumour genomics, imaging data, and real-world outcomes to help clinicians select the most effective therapies for individual patients. Finally, in drug development, AI can identify promising compounds and targets, shortening traditional development cycles and discovering new uses for existing medicines.

Challenges That Cannot Be Ignored

However, the report also highlights significant risks associated with AI in cancer care. Key concerns include regulatory gaps as AI tools advance faster than current rules, making it challenging to ensure they remain safe, accurate, and accountable. Many promising AI systems require further validation in real-world clinical settings, as untested tools could lead to misdiagnoses or unsafe decisions. Bias and inequity are also risks, since AI trained on unrepresentative data may produce less accurate recommendations for specific patient groups. Implementation barriers, such as limited infrastructure, funding, and trained staff, can hinder the integration of AI into everyday healthcare. Finally, trust issues may arise, as both patients and clinicians need to understand and have confidence in AI systems for them to be effectively adopted.

Policy Recommendations: A Roadmap for Safe and Effective Use

To tackle these challenges, the report puts forward four key recommendations. First, it calls for national standards and validation frameworks, including speciality-specific rules and post-market monitoring of AI tools. Second, it emphasises the importance of training and literacy, proposing pan-European AI education to ensure that at least 50% of oncology professionals are confident in using AI by 2030. Third, the report urges robust regulatory guidance and oversight, including EU-wide support for data protection under GDPR, implementation of the AI Act, and strong patient engagement to ensure clinical accountability. Finally, it highlights the need for investment in data infrastructure, leveraging the European Health Data Space to harmonise systems, modernise cancer registries, and build representative datasets that support safe and effective AI deployment.

Why This Matters for Kapa3

Building on these advancements, K3 is preparing to launch its digital assistant, “Myrto”, in 2026. Designed to harness the power of AI, “Myrto” will support patients and healthcare professionals across the cancer care pathway. By integrating cutting-edge AI capabilities with user-friendly guidance, “Myrto” exemplifies K3’s commitment to improving outcomes, streamlining workflows, and empowering both patients and clinicians in Europe’s rapidly evolving healthcare landscape.

To see the full article, please click here.

https://www.europeancancer.org/resources/publications/harnessing-ai-for-cancer-care-in-europe.html

When Art Meets Science: How CREATE Platform May Strengthen Emotional Regulation in Cancer Care

At Kapa3, we recognize that cancer affects far more than the body, challenging the emotions, sense of self, relationships, and quality of life of those suffering. Despite the high prevalence of co-occuring mental health issues such as anxiety and depression, access to mental health services remains limited. This gap between patient needs and healthcare provisions is precisely what motivated us to help develop CREATE, an innovative digital platform designed to support emotional resilience through a powerful combination of art, technology, and emotional engagement (Ladas et al., 2025).

The CREATE (Creative and Resilience through Arts, Technology, and Emotions) platform uses computerised cognitive training (CCT) designed to enhance emotional regulation by integrating working memory training, engagement with famous artwork, and creative emotional expression. Unlike other platforms, it only targets one cognitive function: working memory. Evidence suggests that focusing on a single cognitive function is more effective than targeting multiple ones. Working memory in particular has been found to influence emotional regulation, a skillset with established benefits for anxiety and depression.

CREATE therefore introduces a unified framework that addresses cognitive function, emotional expression, and biological influences such as sleep quality and dopamine activity. Such digital health solutions are increasingly recognized as promising alternatives to standard psychotherapy, offering greater accessibility and affordability while still capable of reducing symptoms of depression and anxiety.

Findings from the pilot study on CREATE were very promising; the participants found the platform easy to use and enjoyable, and showed increased emotional and creative engagement. Although this early research focused on feasibility and validity rather than therapeutic effectiveness, initial findings indicate improvements in emotional regulation. Importantly, the study demonstrated positive relationships between working memory, emotional regulation, and expression of emotion, while also suggesting that sleep and dopamine may mediate these effects.

These insights highlight the importance of lifestyle and biological data in developing personalized digital mental health tools. It is well established in neuroscience that working memory plays a central role in emotional regulation. A stronger working memory allows individuals to better cope with distressing thoughts, shift their attention, and respond more calmly to challenges. For people living with cancer, supporting these cognitive and emotional capacities makes daily life more manageable. Improved thinking skills can facilitate treatment adherence, informed decision-making, and a more effective management of the emotional turbulence that often accompanies illness.

The study relied on a convenience sample made up mostly of cancer-related healthcare professionals, and only one cancer survivor participated. To address this limitation, the next phase of research will focus entirely on cancer patients and survivors. Their unique challenges, including cancer-related fatigue and treatment-related cognitive changes, will be central to refining the platform and ensuring that CREATE is tailored to the needs of those it aims to benefit the most. This creates not only a more impactful intervention but also empowers patients to have a voice in shaping the future of supportive cancer care.

As we look ahead, CREATE offers a hopeful vision for digital mental-health support. It is scalable, affordable, and adaptable, making it especially valuable for people who lack access to mental health care. Intervening early and supporting emotional well-being throughout treatment and survivorship may reduce the long-term strain on healthcare services associated with mental health conditions.  As cancer treatment continues to evolve, we must make sure that psychological care develops along with it. And CREATE does just that.

Read the full study

References

Ladas, A. I., Katsoridou, C., Gravalas, T., Klados, M. A., Stravoravdi, A. S., Tsompanidou, N., Fragkedaki, A., Bista, E., Chorafa, T., Petrovic, K., Vlotinou, P., Tsiakiri, A., Papazisis, G., & Frantzidis, C. A. (2025). Creativity and REsilience Through Arts, Technology and Emotions: A Pilot Study on the Feasibility and Validity of the CREATE Platform. Brain Sciences, 15(11), 1171.

‌Article by Despina Chrysostomidou, Psychologist, for Kapa3 Research Insights

Scientific Seminar: Psychosocial Support after Cancer Treatment and Post-Traumatic Growth

The Psychology Laboratory of INEB/CEST (Institute of Applied Biosciences / CERTH), with the support of the Municipality of Thessaloniki, is organizing on Saturday, 1 November 2025 (10:00–15:00), at the “Manolis Anagnostakis” Hall of the Thessaloniki City Hall, the scientific seminar “Psychosocial Support after Cancer Treatment and Post-Traumatic Growth.”

The event, initiated by the Psychology Laboratory as part of the IC-GROWTH research project, focuses on the psychological and social dimensions of life after cancer treatment, highlighting good practices for care, empowerment, and post-traumatic growth.

The program includes expert presentations and an open discussion with the audience, featuring researchers, healthcare professionals, and representatives from patient associations.

Participation is free, but pre-registration is required through the following form:
Registration Form

This seminar offers a valuable opportunity for learning and sharing experiences on psychosocial support and care after cancer treatment.

Kapa3 supports initiatives that strengthen mental health and quality of life for individuals who have experienced cancer.

Date: Saturday, 1 November 2025
Time: 10:00–15:00
Location: “Manolis Anagnostakis” Hall, Thessaloniki City Hall

October 25 – World Breast Cancer Awareness Day

October 25 has been established as World Breast Cancer Awareness Day, a day dedicated to raising awareness, promoting prevention, and supporting people living with this disease. Breast cancer is the most commonly diagnosed cancer among women worldwide, affecting approximately 2.3 million women each year, with 670,000 deaths, while in Greece around 6,000 new cases are diagnosed annually (Source: Globocan 2025). These are not just numbers—they are mothers, sisters, daughters, and friends who deserve hope and dignity.

Survival chances depend on access to early detection and effective treatment: in high-income countries, the five-year survival rate exceeds 90%, while in countries such as India it is 66% and in South Africa only 40%. These inequalities highlight the urgent need for coordinated international action, as incidence and mortality are projected to rise by 40% by 2050 if current trends continue.

Breat scancer does not affect only women—around 1% of diagnoses occur in men, a fact often overlooked. Awareness and education must be inclusive so that no one is left unprotected.

The WHO Global Breast Cancer Initiative, established in 2021, works with countries to reduce breast cancer mortality by strengthening health systems and facilitating access to diagnosis and treatment.

At the same time, psychosocial support for patients and their families is crucial, as a diagnosis affects all aspects of life, from work to daily routines and mental well-being.

International Breast Cancer Awareness Day also calls on communities, health organizations, and authorities to collaborate to improve access to screening and treatment services. Raising awareness about risk factors—such as genetics, age, and lifestyle—and promoting healthy habits helps prevent the disease and reduce health inequalities.

Every individual can contribute: schedule a mammogram, remind friends to do the same, support nonprofit organizations, or participate in awareness activities. Even small gestures, like wearing a pink ribbon or sharing reliable information on social media, make a difference.

At Kapa3, we believe that every woman and person living with cancer deserves support, knowledge, and access to high-quality treatments. Through initiatives in awareness, social support, and empowerment, our goal is to build a society where no life is endangered by lack of information, resources, or care, and wher

e hope and solidarity become powerful allies in the fight against the disease.

Read more on breast cancer:

https://www.kapa3.gr/en/raising-the-standards-europe-s-qa-scheme-for-breast-cancer-services/

Understanding Breast Cancer Risk Factors: What You Can and Can’t Change

October – Breast Cancer Awareness Month

Sources: https://gco.iarc.fr/en

https://www.who.int/initiatives/global-breast-cancer-initiative

https://www.who.int/news-room/fact-sheets/detail/breast-cancer

Text/adaptation: Ifiyenia Anastasiou for Kapa3

KAPA3 at the ESMO Congress: Inspiration and Confirmation That We Are Moving Towards the Future

From October 17 to 20, we attended the ESMO World Congress in Berlin. The event stood out for the active participation of the Greek medical community, which led presentations on clinical data, Real-World Evidence, and up-to-date education in collaboration with the global oncology community. At the same time, Greek teams received awards in various areas (medical, nursing, institutional), inspiring us all with hope for the ongoing developments in oncology care.

Our main goal as KAPA3 was to focus on research addressing the real needs of the population within the framework of the global community. Collaborating with healthcare professionals from around the world allowed us to gather valuable knowledge and experiences. The intensive sessions and discussions broadened our understanding and prompted reflection on the next steps.

Key challenges identified for the patient advocacy community were:

  1. Mandatory multidisciplinary assessment before starting treatment
    No patient should begin treatment without undergoing a multidisciplinary assessment, including an oncology nurse, social scientist, and psychologist. This should be considered the minimum standard for all cancer patients.
  2. Certification and quality of multidisciplinary teams
    It is our duty to ensure that these teams meet quality standards. Their certification is undoubtedly complex. However, for us at KAPA3, multidisciplinary care is a fundamental criterion for service provision and must be certified. Quality care can significantly improve patient outcomes, as shown by clinical studies and research presented at this year’s congress, with potential improvements in overall survival of up to 10% (Sweden).

We are deeply proud that our work is guided by these standards precisely. In an era of remarkable progress in medicine and new therapies, we continue to strengthen the institution of research and multidisciplinary care, ensuring accessibility and patient-centered approaches aimed at quality of life.

This is the third time we have presented our efforts at an ESMO congress, in collaboration with the International University and the Nursing Department, highlighting our presence at every level. Meanwhile, trainings for other healthcare professionals take place annually within our organization in collaboration with Greek universities.

For Greek patients and their environment, we have not yet reached a point where the quality of care is considered a key objective for the entire oncology community. Our aim is to align with efforts across Europe so that, in the future, multidisciplinary assessments from the first day of diagnosis become standard practice within therapeutic protocols.

At KAPA3, we understand that quality care, inherently multidisciplinary, requires collective effort and collaboration between organizations and professionals to determine the best possible standards.

Continuing the Journey: Holistic Body and Mind Care with Kapa3 and the University of the Peloponnese

After the first round of meetings held in April (see the related article here), focusing on Nutritional Guidance and Experiential Psychological Support, Kapa3 and the University of the Peloponnese continue their collaboration with a new series of experiential workshops dedicated to the holistic care of body and mind.

The meetings are open to people living with cancer, caregivers, and healthcare professionals — to anyone seeking a space for genuine communication, understanding, and empowerment.

In this new cycle, mental health and nutrition are approached as two sides of the same care.

In the mental health sessions, participants learn to recognize and manage challenging emotions such as anxiety or fear, strengthen their resilience, and cultivate a deeper connection with themselves and others.

At the same time, the nutrition sessions explore how balanced and mindful eating can support the body, enhance energy and mood, and become an act of self-care and self-respect. Food is not only a necessity but also a way to show love — to the body, the soul, and to life itself.

The meetings are held online and are based on dialogue, experiential learning, and the sharing of personal experiences. Everyone participates at their own pace, in a warm environment of acceptance and trust.

To express your interest: Registration Form for the Support Group for People with Cancer

Text/adaptation: Ifiyenia for Kapa3

World Palliative Care Day – 11 October 2025

“Leave no one behind: Equity in access to palliative care.”

World Palliative Care Day is a moment to recognize that healthcare is not only about curing disease — it’s also about caring, comforting, and preserving dignity until the very end. Everyone deserves the best possible care, regardless of who they are or where they live.

Globally, more than 50 million people die each year, and it is estimated that around 60% would benefit from hospice and palliative care. Yet access remains deeply unequal: only about 14% of the 73 million adults and children who need palliative care actually receive it. Most of this need is met in high-income countries, while in low- and middle-income regions only 4% of the population in need is served. The COVID-19 pandemic has further exposed these disparities, highlighting the urgent need to integrate palliative care into public health systems worldwide.

Palliative care is about the whole person — their physical comfort, emotional well-being, social environment, and spiritual peace. It aims to ease pain and suffering while supporting families and caregivers through counselling, practical help, and compassion. Studies show that early integration of palliative care in cancer treatment can improve symptom control, quality of life, and even survival rates.

According to the World Health Organization, palliative care development should follow a public health approach that includes policy, education, medicine availability, and community empowerment. In many countries, especially where health resources are limited, training healthcare professionals and raising public awareness can make a real difference. Local communities, volunteers, and patient organizations play a vital role in reaching those who might otherwise be left behind — offering presence, empathy, and human warmth that no medical intervention can replace.

In Greece, the Hellenic Society of Medical Oncology (HeSMO) has emphasized the importance of developing a national palliative care framework. Every year, more than 120,000 people in Greece are estimated to need such care — nearly 37% of them cancer patients — but specialized services remain limited, particularly outside large cities. The HeSMO position paper calls for education, policy support, and the inclusion of palliative care at all levels of the healthcare system.

At Kapa3, we stand with patients and families who face serious illness. Through awareness, advocacy, and human connection, we work toward a healthcare model that values quality of life as much as longevity. Palliative care is not about giving up — it’s about living fully, with dignity, comfort, and compassion, every step of the way.

Read more here

World Mental Health Day

Every year on 10 October, the world raises its voice for mental health. The World Health Organization reminds us that there is no health without mental health — a truth that is especially important for people living with cancer.

A cancer diagnosis, the treatments, and the uncertainty about the future can create a heavy emotional burden. Many patients experience anxiety, sadness, or feelings of isolation. Studies show that around 30% of people with cancer face psychological challenges such as depression or post-traumatic stress — conditions that affect not only mood but also treatment outcomes and overall well-being.

Psychological distress is not merely a natural reaction to illness; it can influence the immune system, increase chronic inflammation, and reduce the body’s resilience. Behaviourally, it may lead to delays in seeking care, poor adherence to treatment, and social withdrawal. That’s why psychological support is an essential component of cancer care.

A growing body of research shows that interventions like cognitive-behavioral therapy (CBT) and mindfulness-based practices significantly reduce anxiety, depression, fatigue, and stress, while enhancing resilience, post-traumatic growth, and quality of life. Mindfulness-based stress reduction (MBSR), art-based mindfulness, and guided meditation are all proven to help patients regain emotional balance and strength.

At Kapa3 – Cancer Guidance Center, we believe care extends beyond medical treatments. Human connection, understanding, and the sense that “you are not alone” can make all the difference. By providing information, support, and a compassionate presence, we aim to lighten the emotional load for both patients and their families.

World Mental Health Day reminds us that caring for the patient is holistic. Cancer is not only a physical battle; it is an emotional journey — and no journey should be faced alone.

References / Learn more:

Kapa3 at the “Latest Developments in Lung Cancer Prevention and Treatment VII” Conference

Kapa3 at the “Latest Developments in Lung Cancer Prevention and Treatment VII” Conference – Highlighting the Social Dimension of Health and Palliative Care

From October 3 to 5, 2025, the “Latest Developments in Lung Cancer Prevention and Treatment VII” conference took place at the Electra Palace Hotel in Thessaloniki, featuring hybrid participation and attracting dozens of healthcare professionals from across Greece. Attendance averaged around 70 participants per hour, reflecting strong interest in both scientific advancements and social aspects of lung cancer care.

At the Round Table “Social and Economic Determinants of Health: The Kapa3 Model” (October 5, 09:00–10:15), Evageli Bista and Anastasia Fragkedaki presented Kapa3’s patient-centered care model, which integrates psychosocial support, information, and empowerment for patients and caregivers.

The discussion focused on the patient’s social context, the impact of socio-economic factors on health outcomes, and the critical importance of palliative care, particularly in Northern Greece where dedicated resources remain limited. Reference was also made to the pilot program “OIKOTHEN”, implemented in collaboration with Kapa3, currently supporting four patients and receiving highly positive feedback, with plans to expand in the future.

Kapa3’s presence at the conference drew notable interest from healthcare professionals, helping to disseminate the organization’s work and philosophy across new scientific communities and healthcare institutions.

Through active participation in key scientific events nationwide, Kapa3 continues to promote the principles of holistic care, collaboration, and solidarity in the fight against cancer.